KDR and neoplasm: VEGFR2 is predominantly expressed in FOXP3+ regulatory T cells (Tregs), promoting their recruitment to tumor sites and suppressing the activation and proliferation of effector T cells, thereby enhancing tumor immunosuppression [103].